These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 24034994)

  • 1. Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens.
    Oba M; Chin K; Kawazoe Y; Takagi K; Ogura M; Shinozaki E; Suenaga M; Matsusaka S; Mizunuma N; Hatake K
    Oncol Lett; 2011 Mar; 2(2):241-245. PubMed ID: 22866071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of fast track surgery for patients with gastric cancer undergoing gastrectomy.
    Chen S; Zou Z; Chen F; Huang Z; Li G
    Ann R Coll Surg Engl; 2015 Jan; 97(1):3-10. PubMed ID: 25519256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage
treatment in refractory or relapsed small cell lung cancer].
    Yu S; Wang Y; Hu X; Wang H; Hao X; Xu J; Li J; Zhang X; Shi Y
    Zhongguo Fei Ai Za Zhi; 2013 Sep; 16(9):470-5. PubMed ID: 24034994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
    Nishikawa M; Miyake H; Fujisawa M
    Int J Clin Oncol; 2016 Feb; 21(1):162-7. PubMed ID: 26123313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer.
    Oshita F; Sugiura M; Murakami S; Kondo T; Saito H; Yamada K
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):345-50. PubMed ID: 23124649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
    Pietanza MC; Kadota K; Huberman K; Sima CS; Fiore JJ; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Chan TA; Rizvi NA; Azzoli CG; Riely GJ; Kris MG; Krug LM
    Clin Cancer Res; 2012 Feb; 18(4):1138-45. PubMed ID: 22228633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan as a second-line monotherapy for small cell lung cancer.
    Sevinc A; Kalender ME; Altinbas M; Ozkan M; Dikilitas M; Camci C;
    Asian Pac J Cancer Prev; 2011; 12(4):1055-9. PubMed ID: 21790251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
    Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
    J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.
    Govindan R; Page N; Morgensztern D; Read W; Tierney R; Vlahiotis A; Spitznagel EL; Piccirillo J
    J Clin Oncol; 2006 Oct; 24(28):4539-44. PubMed ID: 17008692
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.